Boston, Massachusetts, United States, November 17, 2026
Corsera Health, Inc., a clinical-stage biotechnology company focused on cardiovascular disease prevention, has announced the initiation of a Phase 1 clinical trial evaluating COR-2003, an investigational small interfering RNA (siRNA) therapy designed to lower blood pressure by targeting angiotensinogen (AGT). The study will also investigate the co-administration of COR-2003 with COR-1004, another investigational siRNA therapy developed to reduce low-density lipoprotein (LDL) cholesterol. This clinical development marks an important step toward creating a dual-targeting RNA interference (RNAi) medicine designed to address two major risk factors associated with cardiovascular disease: elevated blood pressure and high LDL cholesterol. The company aims to develop a preventive treatment strategy that could eventually be administered through a once-annual subcutaneous injection, potentially reducing the burden of long-term cardiovascular risk management. The Phase 1 trial is being conducted in Australia and New Zealand and represents the first clinical evaluation of this combined RNAi approach.
COR-2003 Targets Angiotensinogen to Reduce Blood Pressure
COR-2003 is an investigational siRNA medicine designed to silence angiotensinogen (AGT) gene expression. Angiotensinogen is a protein produced primarily in the liver and serves as a precursor in the renin-angiotensin system, which plays an important role in regulating blood pressure and fluid balance. By using RNA interference technology, COR-2003 is designed to reduce the production of AGT messenger RNA, ultimately lowering angiotensinogen protein levels and potentially reducing blood pressure. This targeted approach aims to provide sustained blood pressure reduction through a single subcutaneous administration rather than requiring frequent daily medication. The investigational therapy is being developed as part of Corsera’s broader strategy to address cardiovascular disease before long-term exposure to major risk factors causes irreversible damage. The company is particularly interested in preventive treatment approaches that could help reduce the cumulative cardiovascular risks associated with elevated blood pressure throughout a person’s lifetime. However, COR-2003 remains an investigational therapy, and its safety, tolerability and blood pressure-lowering potential must be established through clinical evaluation.
Phase 1 Trial Evaluates COR-2003 Alone and in Combination
The Phase 1 study is a two-part, randomized, double-blind, placebo-controlled clinical trial involving healthy adult volunteers. In Part A, researchers will evaluate single-ascending doses of COR-2003 administered independently to assess its safety and tolerability. The study will also investigate pharmacokinetic and pharmacodynamic characteristics, including AGT reduction and changes in blood pressure. In Part B, investigators will evaluate the co-administration of COR-2003 and COR-1004, assessing the safety and biological effects of targeting both AGT and PCSK9. COR-1004 is another investigational siRNA therapy designed to reduce PCSK9 production, a protein involved in regulating LDL cholesterol levels. By targeting PCSK9, COR-1004 aims to lower circulating LDL cholesterol, an established risk factor for atherosclerotic cardiovascular disease. The combined approach is intended to evaluate whether simultaneously reducing AGT and PCSK9 can address two important cardiovascular risk pathways. Participants will be followed for 12 months, allowing investigators to assess treatment tolerability, pharmacokinetics, pharmacodynamics and the durability of biological effects. The study is designed to evaluate safety at Day 90 as a key primary assessment, with additional measurements of AGT knockdown, PCSK9 knockdown, blood pressure reduction and LDL cholesterol changes.
Dual-Targeting RNAi Strategy Advances Cardiovascular Prevention
The development of COR-2003 alongside COR-1004 reflects Corsera Health’s broader ambition to transform cardiovascular disease prevention through RNAi-based medicines. According to the company, the proposed dual-targeting preventive therapy is designed to reduce cumulative exposure to both elevated LDL cholesterol and high blood pressure, two major contributors to atherosclerotic cardiovascular disease. Atherosclerosis occurs when fatty deposits accumulate within arterial walls, narrowing blood vessels and increasing the risk of serious cardiovascular complications, including heart attacks and strokes. Corsera believes that sustained suppression of these biological risk factors could offer a new preventive approach for individuals who may benefit from long-term cardiovascular risk reduction. The company expects initial proof-of-concept data from the COR-2003 clinical cohorts in early 2027, followed by initial data from the combined COR-1004 and COR-2003 cohorts in mid-2027. Based on these development milestones, Corsera plans to initiate a Phase 2 study of its dual-targeting preventive RNAi medicine by the end of 2027. Beyond its therapeutic programs, the company is also developing Klotho, an artificial intelligence-powered platform designed to predict an individual’s lifetime cardiovascular disease risk and estimate the potential benefits of lowering LDL cholesterol and blood pressure.
Overall, the initiation of the COR-2003 Phase 1 trial represents an important milestone in RNA interference-based cardiovascular drug development. If successful, the dual-targeting strategy could provide a new approach to long-term cardiovascular prevention through sustained control of two major disease risk factors. The upcoming clinical findings will be important in determining the safety, biological activity and future development potential of this investigational medicine.
Source: Corsera Health press release



